Moberg Pharma AB (publ) (MOB) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Moberg Pharma telephone conference. My name is Charlie and I'll be coordinating the call today. If you'd like to ask a question at the end of the presentation you can do so by pressing star 5 by 1 on the telephone keypad. I will now hand over to our host Anna Young, CFO, to begin. Anna, please go ahead. Thank you and welcome to this telephone conference following the press release this morning. And this call will be recorded and uploaded on our webpage following completion. So with me today, I have our Chief Medical Officer Anders Bredesen and our Chief Scientific Officer Amir Tavakol. And before opening up for questions, I would like to provide a short summary on the information that we received this morning. So in essence, we received information about clinical cure in a subset of patients for our North American phase 3 study for MOB15 against onychomycosis. And the number of patients who have achieved clinical cure in this blinded subset of patients is lower than our expectations. And clinical cure, that's the sufficient assessment of the amount of affected nail area for a patient. For clinical cure, this has to be zero. you are perfectly healthy looking male without any abnormalities. In total, there are three parameters, clinical cure, negative frontal culture, and negative microscopy, together that make up the complete cure, which is the study's primary endpoint, the direction that Tessier will look at. All three need to be met. So a low clinical cure means that complete cure also has to be low. The information that we have received is blinded. We don't know if a patient has received the drug or not, and also do not know the percentage of patients receiving drugs in this sample. However, the total number that we have achieved o...